Brokerages Set Indivior PLC (NASDAQ:INDV) Price Target at $39.33

Shares of Indivior PLC (NASDAQ:INDV) have earned an average rating of “Buy” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $39.3333.

A number of equities analysts recently commented on INDV shares. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Northland Securities set a $50.00 price target on shares of Indivior in a research note on Tuesday, January 20th. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, March 17th. Finally, HC Wainwright raised their price objective on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th.

Insider Transactions at Indivior

In other Indivior news, Director Stuart A. Kingsley bought 940 shares of Indivior stock in a transaction on Friday, March 6th. The shares were bought at an average cost of $31.86 per share, for a total transaction of $29,948.40. Following the acquisition, the director directly owned 5,582 shares in the company, valued at $177,842.52. This represents a 20.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.74% of the stock is currently owned by company insiders.

Institutional Trading of Indivior

A number of large investors have recently modified their holdings of INDV. CWM LLC purchased a new position in Indivior in the third quarter valued at $25,000. Quarry LP purchased a new stake in Indivior during the 3rd quarter worth about $26,000. Raymond James Financial Inc. purchased a new stake in Indivior during the 2nd quarter worth about $26,000. Salomon & Ludwin LLC acquired a new stake in Indivior in the 4th quarter valued at about $30,000. Finally, Harbor Capital Advisors Inc. raised its position in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after purchasing an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Stock Performance

Indivior stock opened at $33.26 on Thursday. Indivior has a fifty-two week low of $10.52 and a fifty-two week high of $38.00. The firm has a 50 day moving average price of $31.81 and a 200 day moving average price of $32.16. The company has a market capitalization of $4.05 billion, a PE ratio of 20.28 and a beta of 0.88.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Friday, February 27th. The company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million for the quarter, compared to analysts’ expectations of $305.62 million. As a group, equities research analysts forecast that Indivior will post 3.08 earnings per share for the current year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.